scispace - formally typeset
F

Frank M. Sacks

Researcher at Harvard University

Publications -  520
Citations -  86842

Frank M. Sacks is an academic researcher from Harvard University. The author has contributed to research in topics: Cholesterol & Weight loss. The author has an hindex of 120, co-authored 490 publications receiving 80422 citations. Previous affiliations of Frank M. Sacks include Erasmus University Rotterdam & University of Texas Health Science Center at Houston.

Papers
More filters
Journal ArticleDOI

Apolipoprotein CIII Induces Expression of Vascular Cell Adhesion Molecule-1 in Vascular Endothelial Cells and Increases Adhesion of Monocytic Cells

TL;DR: The findings provide the first evidence that apoCIII increases VCAM-1 and ICAM- 1 expression in ECs by activating PKCβ and NF-&kgr;B, suggesting a novel mechanism for EC activation induced by dyslipidemia.
Journal ArticleDOI

2021 Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement From the American Heart Association.

TL;DR: The importance of dietary patterns beyond individual foods or nutrients, underscores the critical role of nutrition early in life, presents elements of heart healthy dietary patterns, and highlights structural challenges that impede adherence to heart-healthy dietary patterns as discussed by the authors.
Journal ArticleDOI

Salt Sensitivity of Blood Pressure: A Scientific Statement From the American Heart Association.

TL;DR: The simplest definition of salt sensitivity of blood pressure (SSBP) states that it is a physiological trait present in rodents and other mammals, including humans, by which the blood pressure of some members of the population exhibits changes parallel to changes in salt intake as discussed by the authors.
Journal ArticleDOI

Safety and Tolerability of Pravastatin in Long-Term Clinical Trials Prospective Pravastatin Pooling (PPP) Project

TL;DR: This prospective analysis indicates that during prolonged exposure, 40 mg of pravastatin is well tolerated, with no excess of noncardiovascular serious adverse events, including liver function abnormalities and laboratory and clinical evidence for myositis.